B+
Bull case
25%
Probability
Target price
$76.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
CNC
CenteneBNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$70.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$56.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-07
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+67.0
Score
AI commentary
News tone is moderately positive after the Q2 earnings beat and higher outlook, but the stock pulled back after the update and membership decline remains prominent. Social coverage, options skew, short interest, employee sentiment, and post-print analyst revisions are unavailable, so confidence should remain moderate rather than high.
RankAlpha Sentiment Codex - 2026-08-07
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-28eventQ2 results and higher 2026 EPS outlookMedium impact
Centene reported Q2 adjusted EPS of $2.51 and raised 2026 adjusted EPS guidance above $4.80; Commercial HBR improved to 79.2% and operating cash flow was $3.59 billion [#SEC-8K-2026-07-28]. The positive print is partly offset by the post-earnings pullback and membership contraction.
2026-11-05catalystMembership contraction may cap near-term reratingMedium impact
June at-risk membership fell to 25.9 million from 28.0 million year over year, including a sharp Marketplace decline. Further market digestion of enrollment losses or medical-cost risk could pressure the stock despite the raised outlook [#SEC-8K-2026-07-28].
2026-12-31catalystMargin recovery and balance-sheet executionHigh impact
The investment case depends on sustaining lower health-benefits ratios, improving profitability across Commercial, Medicare, and Medicaid, and continuing debt reduction. Q2 showed segment progress, but the approximately $0.50 of non-recurring items embedded in the guidance increase reduces forward visibility [#SEC-8K-2026-07-28].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-07 • Updated nightlySource: Internal modelMethodology